Allogeneic CAR-T Study – Healthy Donor Cells Outperform Patient Cells in Cancer Therapy

Allogeneic CAR-T Study - Healthy Donor Cells Outperform Patient Cells in Cancer Therapy

A new Allogeneic CAR-T study has shown CAR-T cells derived from healthy donors to be superior at fighting cancer compared to CAR-T cells derived from patients. [1] In a press release, biotechnology company Allogene Therapeutics announced preclinical results from their study on the treatment of multiple myeloma using allogeneic CAR-T cell therapy. Multiple myeloma is […]

Effective Solutions to Cell Therapy Supply Chain & Logistics

Cell Therapy Supply Chain & Logistics

Where the Cell Therapy industry is facing an ever-growing complexity in supply chain and logistics, now is the time to optimize the cell therapy supply chain to create a dependable supply of cellular therapeutics. Adam Clark, Director of Commercial Operations here at Excellos recently attended the Supply Chain & Logistics for Cell Therapies Summit in […]

Cell Therapies – Building Solid Foundations for Success

Building Solid Foundations for Successful Cell Therapies

Raw material experts Dr. David Wellis and Dr. Robert Tressler want to share their knowledge on how to select and source cellular starting materials that build the foundations of successful cell therapies. Dr. Wellis and Dr. Tressler are life sciences experts; both boast decades of experience at the forefront of biomedical research and technology. Mere […]

Part 2: Donor Immune Cell Characterization and Successful Cell Therapy

Donor Immune Cell Characterization and Successful Cell Therapy

Next-level donor immune cell characterization can be used as a foundation for promoting high patient response rates. Last week in Part 1 of our donor characterization series, we dove into T cell function and donor immune cell characterization, and how those factors affect how well a patient may respond to immunotherapy. In Part 2 of […]

TIL Therapy – Encouraging Results for Treating Metastatic Lung Cancer

TIL Therapy - Encouraging Results for Treating Metastatic Lung Cancer

Scientists at the H. Lee Moffitt Cancer Center in Florida are investigating the potential for using tumor infiltrating lymphocytes (TIL therapy) in the fight against metastatic lung cancer. [1] PD-1 immune checkpoint inhibitors and CAR T cell therapies are some of the most promising cancer treatments developed in recent years to help fight aggressive cancers. […]

Anti-PD1 Cancer Treatment – Excellos T Cells Aid Evaluation

Excellos T Cells Aid Evaluation of Anti-PD1 Cancer Treatment

Scientists at GSK in Waltham, Massachusetts, are using Excellos-sourced T cell starting material for their preclinical evaluation of an anti-PD1 antibody. Programmed Cell Death Protein-1 (PD-1) is a transmembrane protein recognized for its role in regulating T cell activity. PD-1 and its analogs are often called “checkpoint inhibitors” because they act as a checkpoint to […]

T Cell Immunotherapy – Excellos Cellular Material Helps Boost Development

Excellos Cellular Material Helps Boost T Cell Immunotherapy Development

T cell immunotherapy is a promising and relatively new field of medicine focused on tailoring a person’s own immune cells to fight disease more effectively. The field has enjoyed early success in the area of cancer immunotherapy, most notably the development of chimeric antigen receptor (CAR) T cells designed to express antigens that specifically target […]